{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:28:31Z","timestamp":1770823711283,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3,1]]},"DOI":"10.1309\/ajcpkivvw4obpx6i","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T17:01:49Z","timestamp":1424970109000},"page":"451-458","source":"Crossref","is-referenced-by-count":12,"title":["Dual HER2 Gene Protein Assay"],"prefix":"10.1093","volume":"143","author":[{"given":"Zaibo","family":"Li","sequence":"first","affiliation":[{"name":"Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Dabbs","sequence":"additional","affiliation":[{"name":"Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine L.","family":"Cooper","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Cancer Institute Biostatistics Facility, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,3,1]]},"reference":[{"key":"key\n\t\t\t\t20180602034154_b1-1430451","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1309\/VE7862V2646BR6EX","article-title":"HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring","volume":"121","author":"Lal","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"key\n\t\t\t\t20180602034154_b2-1430451","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3816\/CBC.2008.n.047","article-title":"Unraveling the biologic and clinical complexities of HER2","volume":"8","author":"Park","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"key\n\t\t\t\t20180602034154_b3-1430451","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20180602034154_b4-1430451","first-page":"410","article-title":"HER2-positive breast cancer: beyond trastuzumab","volume":"24","author":"Murphy","year":"2010","journal-title":"Oncology (Williston Park)"},{"key":"key\n\t\t\t\t20180602034154_b5-1430451","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180602034154_b6-1430451","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1309\/AJCPL5IV0LAWSERG","article-title":"Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas","volume":"138","author":"Hirschmann","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"key\n\t\t\t\t20180602034154_b7-1430451","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1746-1596-7-60","article-title":"A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections","volume":"7","author":"Nitta","year":"2012","journal-title":"Diagn Pathol"},{"key":"key\n\t\t\t\t20180602034154_b8-1430451","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1309\/KFKDNK8CENVN24VU","article-title":"The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management","volume":"129","author":"Striebel","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"key\n\t\t\t\t20180602034154_b9-1430451","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180602034154_b10-1430451","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/path.1313","article-title":"Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres","volume":"199","author":"Dowsett","year":"2003","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20180602034154_b11-1430451","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1309\/AJCPUQB18XZOHHBJ","article-title":"Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases","volume":"134","author":"Grimm","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"key\n\t\t\t\t20180602034154_b12-1430451","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/jclinpath-2011-200019","article-title":"HER2 gene amplification in patients with breast cancer with equivocal IHC results","volume":"64","author":"Meijer","year":"2011","journal-title":"J Clin Pathol"},{"key":"key\n\t\t\t\t20180602034154_b13-1430451","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1080\/02841860801989779","article-title":"Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002\u20132006: a nationwide study including correlation between HER-2 status and other prognostic variables","volume":"47","author":"Rasmussen","year":"2008","journal-title":"Acta Oncol"},{"key":"key\n\t\t\t\t20180602034154_b14-1430451","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.971","article-title":"Evaluating HER2 amplification and overexpression in breast cancer","volume":"195","author":"Bartlett","year":"2001","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20180602034154_b15-1430451","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-0428-03","article-title":"Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization","volume":"10","author":"Isola","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20180602034154_b16-1430451","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1440-1827.2010.02553.x","article-title":"Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH)","volume":"60","author":"Kato","year":"2010","journal-title":"Pathol Int"},{"key":"key\n\t\t\t\t20180602034154_b17-1430451","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/modpathol.2011.9","article-title":"Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer","volume":"24","author":"Koh","year":"2011","journal-title":"Mod Pathol"},{"key":"key\n\t\t\t\t20180602034154_b18-1430451","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/PAS.0b013e3181d96231","article-title":"Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility","volume":"34","author":"Papouchado","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"key\n\t\t\t\t20180602034154_b19-1430451","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4048\/jbc.2011.14.4.276","article-title":"Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer","volume":"14","author":"Park","year":"2011","journal-title":"J Breast Cancer"},{"key":"key\n\t\t\t\t20180602034154_b20-1430451","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/PDM.0b013e31817f5227","article-title":"The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer","volume":"18","author":"Pedersen","year":"2009","journal-title":"Diagn Mol Pathol"},{"key":"key\n\t\t\t\t20180602034154_b21-1430451","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1309\/AJCP6CXS8OSRHXIR","article-title":"Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases","volume":"141","author":"Gao","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"key\n\t\t\t\t20180602034154_b22-1430451","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1309\/AJCP13GJAOJAYJMW","article-title":"Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer","volume":"139","author":"Mansfield","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"key\n\t\t\t\t20180602034154_b23-1430451","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/01.pas.0000172294.67409.4f","article-title":"Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast","volume":"29","author":"Downs-Kelly","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"key\n\t\t\t\t20180602034154_b24-1430451","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.pai.0000213138.01536.2e","article-title":"PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2\/neu) status in breast cancer","volume":"15","author":"Ni","year":"2007","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/143\/3\/451\/24998778\/ajcpath143-0451.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T05:24:17Z","timestamp":1566365057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/143\/3\/451\/1767172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,1]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,1]]},"published-print":{"date-parts":[[2015,3,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcpkivvw4obpx6i","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,3,1]]},"published":{"date-parts":[[2015,3,1]]}}}